secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2021-10-04T23:59:59+00:00
Accession:  0001193125-21-290428
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

CytomX appoints Alan Ashworth, Ph.D., FRS to Board of Directors as Class III director
--------------------------------------------------------------------------------

- Appointment effective Sept 29, 2021, filling a vacancy; term expires at 2024 annual meeting.
- Standard non-employee director compensation, including option for 40,000 shares vesting monthly over 3 years.
- Company will enter into a standard indemnification agreement with Dr. Ashworth.
- No transactions exceeding $120,000 involving Dr. Ashworth; no arrangements for appointment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000119312521290428/0001193125-21-290428-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000119312521290428/d233551d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-290428

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer